Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of ...

The recent funding marks the first investment of U.S. pharma giant Merck Sharp & Dohme (MSD) in a health tech startup in Asia Pacific. (MSD is the brand that Merck uses to operate outside the U.S ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...